Markets
Will hormone therapy for menopause be officially recommended over non-hormonal treatments by the Endocrine Society by September 2026?
Yes0%No0%
Loading...
About this market
This market resolves to Yes if the Endocrine Society publicly announces, by September 2026, that hormone therapy is recommended over non-hormonal treatments (including fezolinetant) for menopause based on official guidelines or recommendations. The announcement must clearly state preference and be available on the Endocrine Society's official communication channels.
Rules
- Market closes at 9/30/2026.
- Logic weighted resolution applies.
Given the current discussions around menopause treatments, I think it's unlikely the Endocrine Society will officially recommend hormone therapy over non-hormonal options by September 2026. Recent studies have shown that while hormone therapy can alleviate symptoms, non-hormonal treatments are gaining popularity due to safety concerns. The market seems to underestimate the weight of evidence against hormone therapy; the risks are still substantial, and women are increasingly looking for alternatives. That said, I can see why some traders might believe in a shift, given pressures from pharmaceutical companies to promote hormone treatments. Overall, I would lean towards a no here, considering the current data trends.
Rationale:The comment provides a well-reasoned perspective on the likelihood of hormone therapy being recommended over non-hormonal treatments, supported by references to recent studies and trends. The scores reflect a strong factual basis with minor uncertainties, a lack of logical fallacies, and high relevance to the market question. The weights prioritize fact-checking due to the reliance on current data trends, while still acknowledging the logical structure of the argument.
It seems unlikely that the Endocrine Society will officially recommend hormone therapy over non-hormonal treatments by September 2026. The ongoing debate around the risks and benefits of hormone therapy has not reached a consensus, and many guidelines aim for individualized treatment based on patient needs rather than a blanket recommendation. It feels premature to assume a shift in advice when the focus has increasingly been on safer alternatives and minimizing risks. The current market price might reflect some optimism, but I don't think it aligns with the complex realities of medical recommendations.
Rationale:The comment provides a well-reasoned perspective on the complexities surrounding hormone therapy recommendations, which is relevant to the market question. It accurately reflects the ongoing debate and the emphasis on individualized treatment, supporting a high score for relevance and a solid score for fact check. The logical structure is sound, with no fallacies detected, though there is a slight emotional appeal in expressing skepticism about the market's optimism. Weights were adjusted to reflect the importance of factual accuracy and logical coherence in this context.
I think it's unlikely that the Endocrine Society will shift their recommendations this soon; there are too many ongoing studies about the long-term effects of hormone therapy vs. alternatives.
Rationale:The comment accurately reflects the current state of ongoing studies regarding hormone therapy and its alternatives, which supports the claim about the Endocrine Society's recommendations. There are no logical fallacies present, and the comment is directly relevant to the market question. The weights emphasize fact-checking and relevance due to the reliance on current research data.
Given the recent studies showing benefits of hormone therapy, I think the market is underestimating the likelihood of a recommendation by September 2026.
Rationale:The comment accurately references recent studies indicating benefits of hormone therapy, which supports the claim about the market's underestimation. It is logically sound and directly relevant to the market question, with a slight emotional appeal. The weights reflect the importance of factual accuracy and relevance in this context.
The odds seem too low for this recommendation to happen by September 2026. The Endocrine Society's previous guidelines have been cautious about hormone therapy, and existing data from the WHI study shows mixed results on risk benefits. I expect they might still favor non-hormonal options.
Rationale:The comment accurately references the Endocrine Society's cautious stance on hormone therapy and the mixed results from the WHI study, which supports a high Fact Check score. It directly addresses the market question regarding the recommendation timeline, ensuring high relevance. The argument is logically sound with no fallacies detected, though it does contain some emotional elements regarding expectations. The weights reflect the importance of factual accuracy and relevance in this context.
the price on this is way off. there's been so much back and forth on hormone therapy in the past few years, plus the Endocrine Society has historically been cautious. i wouldn't be surprised if they recommend it, but by 2026? maybe a 40 percent chance seems more realistic. non-hormonal options are still pretty popular and well-studied.
Rationale:The comment provides a reasonable assessment of the uncertainty surrounding hormone therapy recommendations, reflecting on the Endocrine Society's cautious history. While it lacks specific data to fully substantiate the claim about the 40 percent chance, it is mostly accurate and relevant to the market question. The weights reflect a balance between factual accuracy and logical reasoning, with a slight emphasis on relevance due to the context of the market.
The current odds seem overly confident in a yes vote. Given the mixed findings from studies around hormone therapy risks and benefits, it feels like a 50-50 at best. The Endocrine Society has historically been cautious about pushing hormone treatments, so I wouldn't be surprised if they stick to non-hormonal approaches for a bit longer. I'd buy into the no side if the spreads improve.
Rationale:The comment accurately reflects the uncertainty surrounding hormone therapy for menopause, citing mixed findings and the Endocrine Society's cautious history. It logically assesses the market odds and expresses a personal investment strategy, which keeps it relevant. The weights reflect a balanced focus on factual accuracy and logical reasoning, with some emotional appeal regarding personal investment. Overall, the comment is well-reasoned and relevant to the market question.
The current price seems low considering the increasing evidence supporting the benefits of hormone therapy for menopausal symptoms; I expect a recommendation soon.
Rationale:The comment accurately reflects a positive outlook on hormone therapy based on increasing evidence, though it lacks specific references to that evidence, leading to a score of 80 for Fact Check. It is logically sound with no fallacies detected, hence a high score in that category. The comment is relevant to the market question but does not delve deeply into the specifics of the recommendation process, justifying a slightly lower score for Relevance. The emotional appeal is present but not overwhelming, leading to a balanced score in Logic/Emotion. The weights emphasize Fact Check due to the reliance on evidence, while No Fallacies and Relevance are also important but slightly less so.
I doubt the Endocrine Society will fully endorse hormone therapy over non-hormonal alternatives by September 2026. The historical hesitance surrounding hormone therapy and its risks makes me think they will continue to recommend a balanced approach.
Rationale:The comment presents a reasonable skepticism regarding the Endocrine Society's potential endorsement of hormone therapy, supported by historical context. While the claim about historical hesitance is accurate, it lacks specific evidence or data to strengthen the argument, leading to a slightly lower score in Fact Check. The comment is logically sound and relevant to the market question, with a balanced emotional appeal, justifying the weights assigned.
It seems pretty unlikely that the Endocrine Society will make such a sweeping recommendation in just a few months; there are so many variables at play with hormone therapy and patient safety. I get that people want clear answers, but it feels overly optimistic to expect a definitive shift in guidelines by September.
Rationale:The comment presents a reasonable skepticism regarding the timeline for the Endocrine Society's recommendations, acknowledging the complexity of hormone therapy and patient safety. While it lacks specific data to fully substantiate its claims, it is logically sound and relevant to the market question. The weights reflect a balanced focus on logical reasoning and relevance, with less emphasis on factual verification due to the speculative nature of the comment.